Merck Sharp + Dohme Corp.

Merck Gmbh

Brian Robert Lahue

Stephane L Bogen

Gerald Wayne Shipps, Jr

Matthew Ernst Voss

Craig R Gibeau

Latha G Nair

Yaolin Wang

Weidong Pan

Yuan Tian

Yao Ma

Ronald J Doll

Timothy J Guzi

Manami Shizuka

Yuan Liu

Mark A McCoy

Margarita Kirova-Snover

Malcolm MacCoss

Corey Strickland

Malcolm Maccoss

Zhuyan Guo

Bheemashankar A Kulkarni

Rumin Zhang

Amin Nomeir

Giovanna Scapin

Danny J Hicklin

Diane Rindgen

Elise M Siegel

Cynthia Seidel-Dugan

W Bent Clayton

The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. 

Substituted piperidines as HDM2 inhibitors

The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Substituted piperidines that increase p53 activity and the uses thereof

In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

Substituted piperidines that increase P53 activity and the uses thereof

Growing community of inventors

Millbury, MA, United States of America

Brian Robert Lahue